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POSITION PIECES 
Unsettling disciplinary frontiers 
An opportunity to address inequities in genetic medicine? 
Emily Hammad Mrig 
Abstract  
Recent advances in genetic research provide anthropologists with an opportunity to reconsider 
the meaning and importance of interdisciplinary research. This piece suggests that 
interdisciplinary thinking can help to redevelop health policies aimed at improving access to 
new genetic technology and addressing many health care inequities. Drawing from research 
on access to genetic testing among women with a breast cancer diagnosis in the United States, 
I explore how patient perspectives can be used to redefine how policy makers interpret the 
utility of genetic medicine. Individuals undergoing genetic testing describe how genetic 
knowledge is translated into salient change in their lives, a view rarely recognized in 
conventional evaluations of genetic medicine. This work also recognizes how the 
‘potentialities’ of genetic medicine both fuel the engine of ongoing genetic research and 
motivate individuals to imagine possible future actions to improve health. This reflection is 
meant to provoke debate and contribute to discussion about how health policies can be 
designed to improve inequities in access to genetic medicine.  
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Introduction 
In a moment of unprecedented advancement in genetic medicine, genetic technology is 
increasingly used to treat disease with the aim of improving individual outcomes and 
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transforming global health. Anthropologists observe that this evolving landscape of genetic 
medicine is producing complex challenges and novel opportunities for medical 
anthropologists to think seriously and reflexively about the meaning of ‘interdisciplinarity’ 
(Gibbon, Kilshaw, and Sleeboom-Faulkner 2018; Taussig and Gibbon 2013). Yet, the existing 
tension between social and life science viewpoints on the merits of genetic medicine often 
constrain the full integration of multiple disciplinary research perspectives.  
Anthropologists are often at odds with the optimistic claims made by clinicians and life 
scientists working in the field of genetic research. We are hesitant to accept the hope and hype 
around genetic medicine largely because genetic research has not yet fulfilled its promise to 
radically transform medicine. Moreover, several anthropologists have emphasized the paradox 
of global expansion and ethical positioning of genetic medicine, which is framed in terms of 
social inclusion and justice, and the reality of inequitable and stratified access to this health 
technology (Gibbon, Kilshaw, and Sleeboom-Faulkner 2018; Taussig and Gibbon 2013). My 
own research on inequitable access to genetic testing among women diagnosed with breast 
cancer validates these assessments and is useful in predicting how these inequities might 
translate to other cases of biotechnology and genetic medicine.  
Rather than parsing out disciplinary points of disagreement on the successes or failures of 
genetic research, ‘interdisciplinarity’ hinges on our ability to think across boundaries and 
recognize areas of mutual agreement on the benefits of genetic medicine. Researchers across 
many disciplines agree that we must address inequities in access to genetic medicine in order 
to expand the use of this biotechnology. I argue that interdisciplinary thinking is particularly 
important for reimagining health policies that will improve access to genetic medicine. 
Interdisciplinary approaches to genetic medicine can become a path towards achieving our 
common goal of improving population health.  
Conventional clinical and health policy perspectives on the utility of genetic medicine assume 
that the technology will be ‘cost-effective’ and used to make actionable decisions around 
disease prevention or intervention. Current policy evaluations on the costs and benefits of 
genetic medicine do not take into account patient perspectives. In this piece, I explore how 
these conventional perspectives provide only a narrow view of the benefit or value of genetic 
knowledge for individuals who experience genetic testing. Developing health policies that 
include patient perspectives on genetic testing alongside conventional approaches is necessary 
to fully recognizing how genetic knowledge is translated into salient benefits for individuals 
and is a critical piece in efforts to broaden access to genetic medicine.  
Drawing from my research with women who experienced a breast cancer diagnosis, I reveal 
how genetic results are a key part of making more informed decisions about breast cancer 
treatment. Genetic results gave these women greater agency to act in health promoting ways. 
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This illustrates how genetic knowledge is empowering and diminishes anxieties about the 
possibility of another cancer diagnosis in the future. Therefore, the value of genetic knowledge 
does not necessarily stem from the possibility of a measurably improved outcome in health, 
but rather from the confidence gained in making informed treatment decisions and the 
opportunity to form a deeper understanding of self.  
Emphasizing the immediate utility of genetic medicine also means that, as a society, we run 
the risk of overlooking how genetic ‘discovery’ generates new uncertainties and research 
questions that drive future biomedical research endeavors. Individuals undergoing genetic 
testing often receive some ‘uncertainties’ with their genetic results, which is caused when there 
is insufficient evidence to classify a gene variant as either detrimental or neutral. I find that 
many research participants perceive these genetic uncertainties as something with ‘value’ 
because these results may become clearer and serve a health promoting purpose sometime in 
the future. 
To further interrogate the benefits gleaned from ‘uncertainties’, I employ the social science 
concept of ‘potentiality’, which recognizes how the uncertainties produced from genetic 
knowledge are a type of insight embedded with latent qualities that may realize future utility 
(Lee 2013; Taussig, Hoeyer, and Helmreich 2013). Potentiality creates a space to consider how 
the benefits of genetic knowledge transcend the clinical encounter and retain their value to 
improve individual health at some unknown future point. Potentiality is not only a useful tool 
for social scientists to examine how individuals interpret genetic uncertainty, but can also be 
valuable in creating interdisciplinary insights on the benefits of genetic medicine as something 
more abstract and not necessarily immediate and measurable. In other words, genetic 
knowledge offers a form of ‘social utility’, rather than clinical and immediate utility (Stivers 
and Timmermans 2017), and can provide an alternative view on what we mean by the ‘utility’ 
of genetic testing. 
US health insurance policies and emerging inequalities 
For US health insurance companies and other organizational bodies tasked with overseeing 
policies on the clinical utility of genomic services, a genetic test should lead to measurable 
changes in prevention, treatment, prognosis, or disease management (Stivers and 
Timmermans 2017). As an example, oncologists are increasingly using the results of genetic 
testing for women with new breast cancer diagnoses, along with other diagnostics, to further 
classify the tumor, fine-tune the cancer treatment strategy, and provide the patient with a 
‘personalized’ therapeutic strategy. This approach is clinically referred to as ‘treatment-focused 
genetic testing’ because the results presumably have immediate and direct implications for the 
management of the disease. Treatment decisions are based on knowledge of specific genetic 
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variants that are ‘clinically actionable’ and have approved therapeutic interventions (Narod 
2018; Stivers and Timmermans 2017). For example, genetic results can inform decisions such 
as: choosing between less invasive surgery to remove the tumor (e.g., lumpectomy) and more 
invasive surgical options (e.g., mastectomy, double mastectomy, etc.); determining 
chemotherapy options; and developing prognosis and risks for future cancers (Yadav et al. 
2018; Katz, Kurian, and Morrow 2015).  
In the USA, health insurance is the primary gatekeeper to most health services and treatments 
and yet previously, very little was known about how different types of plans (e.g., PPO, HMO, 
Medicaid, etc.) impact access to specific types of health care, including genetic testing. I set 
out to investigate the role of health insurance in access to care through a case study of access 
to genetic testing among women diagnosed with breast cancer. My research confirms prior 
findings indicating the high variability in health insurance coverage of genetic testing across 
different types of health insurance payers and plans (Phillips 2018). Although genetic testing 
among newly diagnosed cancer patients can be a cost-effective strategy for treating breast and 
other forms of cancer (Tuffaha et al. 2018), health insurance payers remain hesitant in 
changing coverage policies to improve reimbursements for genetic testing. Hesitation on the 
part of health payers primarily stems from health policy assumptions that new medical 
technology will be a major source of financial risk. From the health insurance perspective, 
coverage of genetic tests should only be available for individuals where there is clear evidence 
that the results are medically ‘necessary’ and the technology is proven to be ‘efficacious’ in 
treating disease.  
This constraint can be traced to the rapid advancement of genetic technology, which generates 
a lag time in the revision of health policies to accurately reflect updates in clinical literature 
and actuarial data. This lag time in payer coverage policy revisions contributes to the uneven 
adoption of new coverage policies on genetic technology and unequal diffusion of genetic 
medicine into clinical practice (Lakdawalla, Malani, and Reif 2017). This disproportionately 
benefits individuals with higher levels of socioeconomic status who often have better-quality 
health insurance (i.e., more comprehensive coverage and lower out-of-pocket costs) and are 
more able to access this genetic testing. Therefore, addressing this problem requires 
reassessing the evidence used to revise health insurance policies on genetic testing. 
Patient perceptions on the benefits of genetic testing 
Patient insights on the advantages of genetic testing are rarely included in clinical literature on 
the efficacy of genetic medicine that is translated into a clinical setting. Yet, I find that when 
individuals have the opportunity to reflect on their breast cancer treatment, they have a strong 
understanding of the ‘actionable’ benefits provided by genetic results. Most of the women 
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participating in my study underwent genetic testing after they were diagnosed, including 
Shonda, who shared: 
After my diagnosis I go see the oncologist, I was thinking chemo the whole way. But 
he said: ‘We need your genetic testing before we can really tell you what type of 
treatment’. With no family history or anything else, and you know, what do they have 
to go on other than the genetic testing? 
Shonda tested negative for gene mutations associated with breast cancer. Equipped with this 
knowledge, her oncologist felt she could safely forego chemotherapy or radiation following 
surgery to remove the cancerous breast tissue.  
In other cases involving participants who tested positive for a BRCA mutation or other genes 
with known associations to breast cancer, genetic results supported their decision to take a 
more aggressive treatment approach. Women with a BRCA1/2 mutation are at a higher risk 
of future breast cancer recurrence (Grindedal et al. 2017). Correspondingly, most of the 
participants who knew they carried a BRCA mutation elected a contralateral prophylactic 
mastectomy as part of their treatment strategy. Savannah had already experienced 
chemotherapy and a lumpectomy as part of her breast cancer treatment when she received her 
genetic results. She was ‘blown away’ by the news that she had a BRCA1 mutation and, 
although the thought of having another surgery was almost unimaginable, she also knew what 
her chances of a recurrence would be if she did not have a contralateral prophylactic 
mastectomy.  
In sum, almost all of the twenty-four participants received genetic testing and felt the 
experience was an empowering component of their treatment decision-making process. Their 
perspectives corroborate clinical research demonstrating the efficacy of treatment-focused 
genetic testing in the improvement of individual disease outcomes (Kurian et al. 2018). Still, 
health payers remain unconvinced at the medical benefits of genetic testing for all newly 
diagnosed breast cancer patients. This is likely because clinical research evaluating ‘successful’ 
translation of genetic knowledge to clinical utility is based on associated mortality outcomes 
from breast cancer.  
This ‘cost-effective’ approach to evaluating the clinical benefit of genetic testing for breast 
cancer patients fails to capture how genetic knowledge facilitates more informed decisions 
about breast cancer treatment and consequently improves the mental and spiritual wellbeing 
of cancer survivors. This point is substantiated by women who did not have genetic testing 
before starting their cancer treatment, all of whom appeared less confident in their treatment 
choices. For instance, Simone underwent genetic testing at the conclusion of her treatment 
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and her results indicated that she had a BRCA2 mutation. Simone commented that if she had 
known this earlier, she ‘probably would have made a different choice and had a double 
mastectomy’. Comments like Simone’s allude to some of the lingering uncertainties felt by 
individuals who have experienced cancer and associated emotional distress (Clayton, Mischel, 
and Belyea 2006; Tewari and Chagpar 2014). 
Potentiality and genetic uncertainty: Future benefits of genetic 
knowledge 
Not all of the genetic knowledge gained from genetic testing is used to make ‘actionable’ and 
immediate treatment-related decisions. Rapid advances in ‘next-generation’ genetic sequencing 
have made it possible for geneticists to simultaneously analyze many different genes and 
today’s new gene panel tests include more than 100 genetic variants (Afghahi and Kurian 
2017). These panel tests will include genes like BRCA1 and BRCA2 that have clear clinical 
guidelines, but also incorporate gene variants that are likely unrelated to breast cancer or lack 
sufficiently robust clinical data to guide patient care (Afghahi and Kurian 2017). Despite this 
shortcoming of panel testing, cancer geneticists argue that panel testing offers more accurate 
information about genes associated with cancer and will improve our appreciation for how 
these other genes are associated with risk of cancer (Kraus et al. 2016). Ultimately, genetic 
researchers view these limitations of genetic testing as crucial in the advancement of genetic 
research and are optimistic this approach will yield the most future benefit. 
To some extent, study participants who had a gene panel test did say they had some lingering 
questions about the meaning of their genetic results; however, patients also echoed the voices 
of geneticists and clinicians who expressed an overwhelming sense of optimism that genetic 
uncertainties can unlock future health breakthroughs. These women were accepting of 
uncertainties because ‘uncertainty’ is a common theme in their breast cancer journey and 
something that could never be fully eradicated (Hall, Mishel, and Germino 2014). They found 
more meaning by focusing on the ‘potentiality’ of genetic uncertainties, opting for a sense of 
hope that this genetic knowledge will continue producing health benefits in a way that does 
not yet – and may never – exist (Taussig, Hoeyer, and Helmreich 2013). The potentialities of 
genetic knowledge open up new territory where individuals hope to ‘discover’ value from 
inconclusive genetic results that has yet to be uncovered.  
Women who had completed breast cancer treatment viewed inconclusive genetic results as an 
indication that health surveillance outside of conventional ‘post-cure’ follow-up care was 
needed. For instance, Bernice tested negative for mutations in genes that have a known 
association with breast cancer, but her results indicated a mutation on a gene variant with an 
unknown significance. Surprisingly, this knowledge brought Bernice comfort because the 
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result ‘made sense’ given the extensive history of cancer among members of her family. 
Bernice was able to construct a self-narrative around why she was diagnosed with breast cancer, 
which resolved some of her prior concerns that she was responsible for causing her cancer 
(Frank 1995; Kaiser 2008). Bernice regained a sense of control over her health that she had 
not felt since before her breast cancer diagnosis. She was hopeful she could prevent future 
cancers by conducting her own research on the gene variant with ‘unknown significance’ to 
see if new insights emerge establishing a link to breast cancer.  
Winona, an oncology nurse, also tested positive for several genes of ‘unknown significance’, 
although her professional experience and extensive family history of breast cancer provoked 
a strong inclination that her breast cancer was hereditary. Like Bernice, she wanted to increase 
her knowledge of genomics to better understand her genetic results. Winona continues to 
schedule semi-annual appointments with her genetic counselor hoping these visits will provide 
knowledge useful to preventing a future breast cancer diagnosis. She explained, ‘I did the full 
panel [genetic] test and an amazing geneticist’ and, because of the inconclusive results of her 
panel testing, Winona ‘really wanted ongoing follow-up. If something else changed and there 
was some other surveillance or treatment I could do, I would do it’. Winona holds no 
expectation that genetic knowledge will provide answers overnight and is willing to stay in this 
‘moment’ of potentiality for as long as necessary.  
Potentialities of genetic testing are most salient in the ways that women perceive the benefits 
of genetic knowledge for other members of their family. Even when the results of genetic 
testing did not have actionable consequences for their breast cancer treatment or were riddled 
with uncertainties, all of the women I spoke with unanimously agreed that the experience was 
important because of the implications for their family. Families seeking genetic knowledge 
from a place of uncertainty again opt for the potentiality of the unknown as a point of 
departure for action; but, now this action is understood within the family and social context 
where health and illness is experienced (Stivers and Timmermans 2017).  
For some participants, because family members are newly equipped with information about 
their family medical history, they can access health insurance coverage for genetic counseling 
and testing services. In addition to immediate family members, participants reported that more 
relatives, including distant cousins and aunts, accessed testing and in some cases were able to 
take preventive action to avoid a future cancer (Katapodi et al. 2018). Potential benefits of 
testing among individuals and families dovetail with clinical research demonstrating that 
current criteria for genetic testing is insufficient to capture individuals with a predisposition to 
hereditary forms of breast cancer, which could prevent cancer in other family members (Chen 
et al. 2018).  
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I found that individuals describe other ways of finding meaning in genetic uncertainties based 
on family conceptions of what ‘runs in the family’ and who in the family is already considered 
‘at risk’. Prior research interrogating the possibility of genetics to transform understandings of 
health show that the implications of results extend beyond the individual, especially when 
results are shared with family, creating new biological ties between family members (Lock et 
al. 2007). Rather than creating anxiety and tension, ambiguous genetic results have the ability 
to become socially actionable, which alleviates feelings of concern (Stivers and Timmermans 
2016). Social actions are many times similar to those taken by individuals who continue to 
research and make meaning out of genetic uncertainties. What differs is the communal sense 
of agency among family members who seek out additional health information that perhaps 
can lend some insights to the genetic results, if not today, then maybe sometime in the future. 
Conclusions 
An interdisciplinary lens shows the value of genetic testing beyond the conventional 
assumption that results must be clinically actionable. Genetic knowledge provides significant 
benefits that often go unrecognized by traditional evaluations of the merits of genetic 
technology. The imperfections and compromises of actual medicine have become a powerful 
and a motivating force to ongoing investments in human and financial resources towards 
biotechnology (Mrig and Spencer 2018; see Warren and Addison, this issue). My research 
shows that the uncertainty of genetic medicine also motivates patients to continue to invest 
their time and financial resources into making meaning out of their results.  
For participants who found the testing beneficial even without ‘conclusive’ knowledge about 
the meaning of results for their health, the promise of genetic medicine has already been 
partially fulfilled. This suggests that individual expectations around the ‘success’ of genetic 
medicine is incongruous with how ‘success’ is perceived by geneticists, clinicians, or even 
health policy makers. 
My research shows that integrating genetic testing into treatment increases the frequency of 
patient engagement with biomedicine. This recurrent engagement with biomedicine occurs 
through multiple pathways, including ongoing surveillance and clinical engagement. For this 
reason, critical social science perspectives remain a necessary component for appreciating the 
ethical and social implications that come with the expansion of genetic medicine into clinical 
and global health settings. Still, recognizing interdisciplinary views on the benefits of genetic 
testing is more than a productive exercise to overcome tensions between life and social science 
perspectives; it also broadens our understanding of the ‘utility’ of genetic results for women 
with breast cancer and deepens our appreciation for the salience of genetic knowledge for 
individuals and their families. This effort may serve as an innovative opportunity to create 
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more equitable health policies to increase access to genetic medicine and lead to our common 
goal of improving global health. 
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